Skip to main content

Table 2 Neutralizing monoclonal antibodies under investigation in clinical trials against COVID-19

From: Potential therapeutic options for COVID-19: an update on current evidence

Target Name Related disease Trial ID
IL-6 receptor Tocilizumab Rheumatoid arthritis NCT04730323
Sarilumab Rheumatoid arthritis NCT04315298
Levilimab Rheumatoid arthritis NCT04397562
IL-6 Siltuximab Rheumatoid arthritis NCT04329650
Clazakizumab Rheumatoid arthritis NCT04494724
Sirukumab Rheumatoid arthritis NCT04380961
Olokizumab Rheumatoid arthritis NCT04380519
IL-1 receptor Anakinra Rheumatoid arthritis NCT04366232
IL1 β Canakinumab systemic juvenile idiopathic arthritis and active Still's disease NCT04362813
GM-CSF receptor Mavrilimumab Rheumatoid arthritis NCT04447469
GM-CSF Lenzilumab Chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia NCT04583969
Gimsilumab Rheumatoid arthritis, multiple sclerosis, asthma, cancer NCT04351243
Otilimab Rheumatoid arthritis NCT04376684
TJ003234 Rheumatoid arthritis, cytokine release syndrome, osteoarthritis NCT04341116
IFN-γ Emapalumab Hemophagocytic lymphohistiocytosis NCT04324021
TNF-α Adalimumab Rheumatoid arthritis NCT04705844
Infliximab Autoimmune diseases NCT04425538
IL-17 Secukinumab Psoriasis, ankylosing spondylitis, psoriatic arthritis NCT04403243
Ixekizumab Autoimmune diseases NCT04724629
IL-12/IL-23 Risankizumab Moderate to severe plaque psoriasis NCT04583956